Treatment of benign prostatic hyperplasia by natural drugs

Csikós, Eszter (avtor), Sollner Dolenc, Marija (avtor), Kenda, Maša (avtor), Kočevar Glavač, Nina (avtor), Farkas, Ágnes (avtor)

Benign prostatic hyperplasia (BPH) is one of the most common urinary diseases affecting men, generally after the age of 50. The prevalence of this multifactorial disease increases with age. With aging, the plasma level of testosterone decreases, as well as the testosterone/estrogen ratio, resulting in increased estrogen activity, which may facilitate the hyperplasia of the prostate cells. Another theory focuses on dihydrotestosterone (DHT) and the activity of the enzyme 5α-reductase, which converts testosterone to DHT. In older men, the activity of this enzyme increases, leading to a decreased testosterone/DHT ratio. DHT may promote prostate cell growth, resulting in hyperplasia. Some medicinal plants and their compounds act by modulating this enzyme, and have the abovementioned targets. This review focuses on herbal drugs that are most widely used in the treatment of BPH, including pumpkin seed, willow herb, tomato, maritime pine bark, Pygeum africanum bark, rye pollen, saw palmetto fruit, and nettle root, highlighting the latest results of preclinical and clinical studies, as well as safety issues. In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.

• Jezik: Angleški jezik
• Ključne besede: benign prostatic hyperplasia, medicinal plants, phytotherapy, saw palmetto, preclinical studies, clinical efficacy, safety issues
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.02 - Pregledni znanstveni članek
• Organizacija: FFA - Fakulteta za farmacijo
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2021
• Št. strani: 32 str.
• Številčenje: Vol. 26, iss. 23, art. 7141
• PID: 20.500.12556/RUL-136713
• UDK: 616.65-007.61
• ISSN pri članku: 1420-3049
• DOI: 10.3390/molecules26237141
• COBISS.SI-ID: 86644739
• Datum objave v RUL: 17.05.2022

Gradivo je del revije

• Naslov: Molecules
• Skrajšan naslov: Molecules
• Založnik: MDPI
• ISSN: 1420-3049
• COBISS.SI-ID: 18462981

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 01.12.2021

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: predklinične študije, klinična učinkovitost, varnostne težave

Projekti

• Financer: EC - European Commission
• Program financ.: Erasmus+, Key Action 2: Strategic Partnerships
• Številka projekta: 2020-1-CZ01-KA203-078218
• Naslov: Open Access Educational Materials on Naturally Occurring Molecules